Your browser doesn't support javascript.
loading
Open a new epoch of arsenic trioxide investigation: ATOdb.
Jiang, Yanan; Li, Jianing; Liu, Yujie; Shen, Xiuyun; Li, Junyi; Zhi, Fengnan; Xu, Juan; Li, Xia; Shao, Tingting; Xu, Yingqi.
Afiliación
  • Jiang Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China; Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical
  • Li J; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
  • Liu Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
  • Shen X; Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Li J; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
  • Zhi F; Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Xu J; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
  • Li X; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
  • Shao T; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
  • Xu Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China; Hohhot Mongolian Medicine of Traditional Chinese Medicine Hospital, Hohhot, 010110, China. Electronic address: xuyingqi1987@163.com.
Comput Biol Med ; 165: 107465, 2023 10.
Article en En | MEDLINE | ID: mdl-37699323
Arsenic trioxide (ATO) is a great discovery in the treatment of acute promyelocytic leukemia (APL), which has been used in an increasing number of malignant diseases. Systematic integrative analysis will help to precisely understand the mechanism of ATO and find new combined drugs. Therefore, we developed a one-stop comprehensive database of ATO named ATOdb by manually compiling a wealth of experimentally supported ATO-related data from 3479 articles, and integrated analysis tools. The current version of ATOdb contains 8373 associations among 2300 ATO targets, 80 conditions and 262 combined drugs. Each entry in ATOdb contains detailed information on ATO targets, therapeutic/side effects, systems, cell names, cell types, regulations, detection methods, brief descriptions, references, etc. Furthermore, ATOdb also provides data visualization and analysis results such as the drug similarities, protein-protein interactions, and miRNA-mRNA relationships. An easy-to-use web interface was deployed in ATOdb for users to easily browse, search and download the data. In conclusion, ATOdb will serve as a valuable resource for in-depth study of the mechanism of ATO, discovery of new drug combination strategies, promotion of rational drug use and individualized treatments. ATOdb is freely available at http://bio-bigdata.hrbmu.edu.cn/ATOdb/index.jsp.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: MicroARNs Límite: Humans Idioma: En Revista: Comput Biol Med Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: MicroARNs Límite: Humans Idioma: En Revista: Comput Biol Med Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos